Literature DB >> 16160207

Cost-effectiveness analysis of treatments for chronic disease: using R to incorporate time dependency of treatment response.

Neil Hawkins1, Mark Sculpher, David Epstein.   

Abstract

When constructing decision-analytic models to evaluate the cost-effectiveness of alternative treatments, we often need to extrapolate beyond the available experimental data, as these typically relate to a limited period starting from the initiation of a new treatment or the diagnosis of the current disease state. We may also be required to extrapolate beyond the available experimental evidence to compare potential treatment sequences. Markov models are often used for this extrapolation. These models have the defining assumption that future transition probabilities are independent of past transitions. This means that, in general, transition probabilities cannot be conditional of the time spent in a given state. Where data exist to show that the risks of transition are conditional on the time spent in the treatment state, the simplifying Markov assumption can result in a loss in the model's "face validity," and misleading results might be generated. Several methods are available to incorporate time dependency into transition probabilities based on standard methods and software. These include the inclusion of tunnel states in Markov models and patient-level simulation, where a series of individual patients are simulated. This article considers the features and limitations of these methods and also describes a novel approach to building time dependency into a Markov model by incorporating an additional time dimension resulting in a "semi-Markov" model. An example of the implementation of such a model, using the R statistical programming language, is illustrated using a cost-effectiveness model for new epilepsy therapies.

Entities:  

Mesh:

Year:  2005        PMID: 16160207     DOI: 10.1177/0272989X05280562

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  14 in total

Review 1.  Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview.

Authors:  Erik J Dasbach; Elamin H Elbasha
Journal:  Pharmacoeconomics       Date:  2017-07       Impact factor: 4.981

2.  Continuous time simulation and discretized models for cost-effectiveness analysis.

Authors:  Marta O Soares; Luísa Canto E Castro
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

Review 3.  A systematic review of the quality of economic models comparing thrombosis inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Authors:  Maximilian H M Hatz; Reiner Leidl; Nichola A Yates; Björn Stollenwerk
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

4.  Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment.

Authors:  Bohdan Nosyk; Daphne P Guh; Nicholas J Bansback; Eugenia Oviedo-Joekes; Suzanne Brissette; David C Marsh; Evan Meikleham; Martin T Schechter; Aslam H Anis
Journal:  CMAJ       Date:  2012-03-12       Impact factor: 8.262

5.  Methods and Study Design for Cancer Health Economics Research: Summary of Discussions From a Breakout Session.

Authors:  Henry J Henk; Ya-Chen Tina Shih; Bijan J Borah
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

6.  Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care.

Authors:  Sylwia Bujkiewicz; Hayley E Jones; Monica C W Lai; Nicola J Cooper; Neil Hawkins; Hazel Squires; Keith R Abrams; David J Spiegelhalter; Alex J Sutton
Journal:  Value Health       Date:  2011-04-30       Impact factor: 5.725

7.  Should the arteriovenous fistula be created before starting dialysis?: a decision analytic approach.

Authors:  Swapnil Hiremath; Greg Knoll; Milton C Weinstein
Journal:  PLoS One       Date:  2011-12-07       Impact factor: 3.240

8.  Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial.

Authors:  Claire Williams; James D Lewsey; Andrew H Briggs; Daniel F Mackay
Journal:  Med Decis Making       Date:  2016-06-08       Impact factor: 2.583

9.  Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling.

Authors:  Claire Williams; James D Lewsey; Daniel F Mackay; Andrew H Briggs
Journal:  Med Decis Making       Date:  2016-10-04       Impact factor: 2.583

10.  A cost-benefit analysis of smoking cessation prescription coverage from a US payer perspective.

Authors:  Christine L Baker; Yao Ding; Cheryl P Ferrufino; Stacey Kowal; Jenen Tan; Prasun Subedi
Journal:  Clinicoecon Outcomes Res       Date:  2018-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.